Maintaining Fat-Free Mass and Muscle Mass during obesity therapy with Incretin-Mimetic Drugs
Obesity is one of the major public health challenges of the 21st century. In recent years, incretin mimetic drugs (IMDs), primarily liraglutide, semaglutide, and tirzepatide, have gained popularity due to their ability to help patients lose 10%-20% of their body weight. However, it has been observe...
Saved in:
Main Authors: | Dariusz Popiela, Karina Urbańska, Łukasz Stojak, Mateusz Grego, Filip Kwiatkowski, Mateusz Baczewski, Katarzyna Grego, Witold Czyż |
---|---|
Format: | Article |
Language: | English |
Published: |
Nicolaus Copernicus University in Toruń
2025-01-01
|
Series: | Quality in Sport |
Subjects: | |
Online Access: | https://apcz.umk.pl/QS/article/view/57000 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Appendicitis After Initiation of Tirzepatide
by: Chan G, et al.
Published: (2025-01-01) -
Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01) -
Tirzepatide in Sport: A Comprehensive Review of its Metabolic Impacts and Potential Applications for Athletes
by: Wiktor Biesiada, et al.
Published: (2025-01-01) -
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01) -
GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01)